Theravance Biopharma
OverviewSuggest Edit
Theravance Biopharma is a biopharmaceutical company which provides medicines to treat serious illnesses. It focuses on several therapeutic areas, including infectious disease, respiratory, gastrointestinal disease, and cardiovascular and renal disease.
| Type | Public | |
| Founded | 1996 | |
| HQ | Dublin, IE | Map |
| Website | theravance.com | |
| Overall Culture | B- | More |
Recent NewsAll News
- Theravance Biopharma, Inc. Reports Third Quarter 2020 Financial Results and Provides Business Update
- Thinking about buying stock in Novan, Energy Focus, Theravance Biopharma, Alphatec, or Jumia Technologies?
- Theravance Biopharma to Report Second Quarter 2020 Financial Results on August 6, 2020
- Theravance Biopharma Appoints Deepika R. Pakianathan, Ph.D. to Board of Directors
Key People/Management at Theravance Biopharma
Rick Winningham
CEO
Gary Barrera
Vice President
Eran Broshy
Director
Dennis O. Driver
Senior Vice President, Human Resources, Organizational and Leadership Development
Reigin Zawadzki
Vice President, Human Resources
Robert V. Gunderson
Director
Theravance Biopharma Office Locations
Theravance Biopharma has offices in Dublin and San Francisco
Dublin, IE (HQ)
Connaught House, 1 Burlington Rd
San Francisco, CA, US
901 Gateway Boulevard
Theravance Biopharma Financials and Metrics
Theravance Biopharma Revenue
Theravance Biopharma's revenue was reported to be $60.37 m in FY, 2018 which is a 292.4% increase from the previous period.
| USD | |
|---|---|
Revenue (FY, 2018) | 60.4m |
Revenue growth (FY, 2017 - FY, 2018), % | 292.4% |
Gross profit (FY, 2018) | 59.7m |
Gross profit margin (FY, 2018), % | 98.8% |
Net income (FY, 2018) | (215.5m) |
EBIT (FY, 2018) | (238.8m) |
Market capitalization (8-Jan-2021) | 1.1b |
Closing stock price (8-Jan-2021) | 17.7 |
Cash (31-Dec-2018) | 378.0m |
EV | 976.7m |
Theravance Biopharma's current market capitalization is $1.1 b.
Annual
Annual
| USD | FY, 2016 | FY, 2017 | FY, 2018 |
|---|---|---|---|
Cash | 344.7m | 89.0m | 378.0m |
Accounts Receivable | 646.0k | 2.3m | 620.0k |
Inventories | 12.2m | 16.8m | |
Current Assets | 528.5m | 378.7m | 532.8m |
Quarterly
| USD | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 |
|---|---|---|---|---|---|---|---|---|---|
Cash | 128.8m | 148.4m | 86.6m | 169.9m | 139.6m | 91.3m | 125.8m | 103.9m | 101.2m |
Accounts Receivable | 1.5m | 1.9m | 873.0k | 1.2m | 1.3m | 1.6m | 2.0m | 3.4m | 3.0m |
Inventories | 9.4m | 9.8m | 12.5m | 13.2m | 12.1m | 15.3m | 17.2m | 17.9m | 17.9m |
Current Assets | 238.8m | 303.1m | 274.0m | 421.5m | 384.9m | 367.1m | 446.8m | 386.7m | 332.6m |
Annual
| USD | FY, 2016 | FY, 2017 | FY, 2018 |
|---|---|---|---|
Net Income | (190.7m) | (285.4m) | (215.5m) |
Depreciation and Amortization | 3.1m | 4.0m | 3.2m |
Inventories | (3.2m) | (7.3m) | (1.6m) |
Accounts Payable | (16.4m) | 3.8m | 3.6m |
Quarterly
| USD | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 |
|---|---|---|---|---|---|---|---|---|---|
Net Income | (42.1m) | (89.4m) | (123.3m) | (65.3m) | (131.6m) | (198.5m) | (65.1m) | (105.9m) | (165.3m) |
Depreciation and Amortization | 699.0k | 1.2m | 1.9m | 1.1m | 2.1m | 3.0m | 900.0k | 1.7m | 2.3m |
Inventories | 134.0k | 157.0k | (1.8m) | 140.0k | (497.0k) | (3.0m) | (371.0k) | (351.0k) | (552.0k) |
Accounts Payable | (9.4m) | (10.8m) | (12.8m) | 2.0m | 4.8m | 3.5m | (449.0k) | (2.3m) | (1.7m) |
| USD | Q1, 2016 |
|---|---|
Financial Leverage | 1.2 x |
Theravance Biopharma Acquisitions / Subsidiaries
| Company Name | Date | Deal Size |
|---|---|---|
| Theravance Biopharma Antibiotics IP | ||
| Theravance Biopharma Ireland Limited | ||
| Theravance Biopharma R&D | ||
| Theravance Biopharma R&D IP | ||
| Theravance Biopharma UK Limited | ||
| Theravance Biopharma US | ||
| Triple Royalty Sub LLC |
Theravance Biopharma Revenue Breakdown
Theravance Biopharma revenue breakdown by geographic segment: 18.4% from Europe, 81.6% from US and 0.0% from Other
Theravance Biopharma Cybersecurity Score
Theravance Biopharma Online and Social Media Presence
Theravance Biopharma's Trends
Theravance Biopharma Company Culture
Overall Culture
B-
75/100
CEO Rating
A
80/100
Compensation
D
54/100
Theravance Biopharma News and Updates
November 05, 2020
Theravance Biopharma, Inc. Reports Third Quarter 2020 Financial Results and Provides Business Update
DUBLIN, Nov. 5, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial results for the third quarter ending September 30, 2020. Theravance Biopharma's Total Revenue for the third quarter 2020 was $18.3 million....
October 14, 2020
Thinking about buying stock in Novan, Energy Focus, Theravance Biopharma, Alphatec, or Jumia Technologies?
NEW YORK, Oct. 14, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NOVN, EFOI, TBPH, ATEC, and JMIA. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
July 27, 2020
Theravance Biopharma to Report Second Quarter 2020 Financial Results on August 6, 2020
DUBLIN, July 27, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, will report its second quarter 2020 financial results and provide a...
July 02, 2020
Theravance Biopharma Appoints Deepika R. Pakianathan, Ph.D. to Board of Directors
DUBLIN, July 2, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company"), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, today announced the...
June 25, 2020
Theravance Biopharma Announces First Patient Dosed in Phase 2 Study of TD-0903 for the Treatment of Hospitalized Patients with Acute Lung Injury Caused by COVID-19
DUBLIN and SOUTH SAN FRANCISCO, Calif., June 25, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company"), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective...
February 12, 2020
Theravance Biopharma Announces Pricing of Public Offering of Ordinary Shares
DUBLIN, Feb. 11, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company"), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, announced today the...
Theravance Biopharma Blogs
January 05, 2021
Theravance Biopharma To Present at the 39th Annual J.P. Morgan Healthcare Conference
Theravance Biopharma To Present at the 39th Annual J.P. Morgan Healthcare Conference
Content Import
Tue, 01/05/2021 - 06:00
Theravance Biopharma To Present at the 39th Annual J.P. Morgan Healthcare Conference
January 5, 2021 at 6:00 AM EST
This release is a ba…
November 17, 2020
Theravance Biopharma to Present at the 3rd Annual Evercore ISI HEALTHCONx Conference
DUBLIN , Nov. 17, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, will webcast a presentation as follows: Evercore ISI 3 rd Annual
October 22, 2020
Theravance Biopharma to Report Third Quarter 2020 Financial Results on November 5, 2020
Theravance Biopharma to Report Third Quarter 2020 Financial Results on November 5, 2020
Content Import
Thu, 10/22/2020 - 06:00
Theravance Biopharma to Report Third Quarter 2020 Financial Results on November 5, 2020
October 22, 2020 at 6:00 AM EDT
This release …
September 01, 2020
Theravance Biopharma to Present at Upcoming Investor Conferences
Theravance Biopharma to Present at Upcoming Investor Conferences
Content Import
Tue, 09/01/2020 - 06:00
Theravance Biopharma to Present at Upcoming Investor Conferences
September 1, 2020 at 6:00 AM EDT
This release is a backfill from a News Wire
…
August 06, 2020
Theravance Biopharma, Inc. Reports Second Quarter 2020 Financial Results and Provides Business Update
- Ampreloxetine and TD-1473 programs progressing towards three data readouts in 2021 - YUPELRI® (revefenacin) gained market share despite COVID-19 impact on market demand - TD-0903 program completed Phase 1, and now enrolling Phase 2 - The Company maintains 2020 financial guidance DUBLIN ,
July 08, 2020
Deepa R. Pakianathan, Ph.D.
Deepa R. Pakianathan, Ph.D.
san.mai@intrado.com
Wed, 07/08/2020 - 14:17
Member of the Audit Committee
Member of the Science and Technology Committee
Deepa
R.
Pakianathan,
Ph.D.
Theravance Biopharma Frequently Asked Questions
When was Theravance Biopharma founded?
Theravance Biopharma was founded in 1996.
Who are Theravance Biopharma key executives?
Theravance Biopharma's key executives are Rick Winningham, Gary Barrera and Eran Broshy.
How many employees does Theravance Biopharma have?
Theravance Biopharma has 363 employees.
What is Theravance Biopharma revenue?
Latest Theravance Biopharma annual revenue is $60.4 m.
What is Theravance Biopharma revenue per employee?
Latest Theravance Biopharma revenue per employee is $166.3 k.
Who are Theravance Biopharma competitors?
Competitors of Theravance Biopharma include Acceleron Pharma, Inflazome and Prothena.
Where is Theravance Biopharma headquarters?
Theravance Biopharma headquarters is located at Connaught House, 1 Burlington Rd, Dublin.
Where are Theravance Biopharma offices?
Theravance Biopharma has offices in Dublin and San Francisco.
How many offices does Theravance Biopharma have?
Theravance Biopharma has 2 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies